SHR- A1811
Sponsors
Jiangsu HengRui Medicine Co., Ltd., Anhui Provincial Cancer Hospital, Tianjin Medical University Cancer Institute and Hospital, Fudan University
Conditions
Advanced Breast Cancer With Ultra-Low HER2 ExpressionBreast CancerEarly Breast CancerGynaecological MalignanciesHER2-Postive Breast CancerHR+ Breast CancerLocally Advanced Breast CancerSHR-A1811
Phase 2
A Study of SHR-A1811 in Subjects With Gynaecologic Oncology
RecruitingNCT05896020
Start: 2023-07-10End: 2026-06-15Target: 225Updated: 2023-08-22
SHR-1811 Combined With Carboplatin in the Treatment of Advanced Breast Cancer With HER2 Expression
Not yet recruitingNCT07047443
Start: 2025-08-01End: 2029-12-31Target: 18Updated: 2025-07-02
SHR-A1811 Plus Pertuzumab as Neoadjuvant Therapy for Early or Locally Advanced HR-Positive HER2-Positive Breast Cancer: A Prospective, Open-Label, Phase II Study
Not yet recruitingNCT07307287
Start: 2025-12-20End: 2027-12-31Target: 30Updated: 2025-12-29
Phase II Study of SHR-A1811 for Ultra-Low HER2 Advanced Breast Cancer
RecruitingNCT07817082
Start: 2026-09-01End: 2029-03-31Target: 30Updated: 2026-09-14
Phase 3
Artificial Intelligence Model-Guided Neoadjuvant Anti-HER2 Targeted Therapy
RecruitingNCT07528716
Start: 2026-05-06End: 2028-06-01Target: 280Updated: 2026-07-08
An Open-Label, Randomized Phase III Study of Trastuzumab Rezetecan With or Without Bevacizumab in First to Third Line BLIS Subtype TNBC
Not yet recruitingNCT07669610
Start: 2026-10-01End: 2029-03-30Target: 140Updated: 2026-06-25
An Open-Label, Randomized Phase III Study of Trastuzumab Rezetecan With or Without Everolimus in First to Third Line LAR Subtype TNBC
Not yet recruitingNCT07760844
Start: 2026-10-01End: 2029-03-30Target: 180Updated: 2026-08-12